Abstracts Archive - Page 1264 of 2425 - ACR Meeting Abstracts

Abstract Number: 877 • 2017 ACR/ARHP Annual Meeting
Modification of the Classification Criteria for Primary Sjögren Syndrome: An International Vignette Survey
Sandrine Jousse-Joulin¹, Florence Gatineau², Chiara Baldini³, Alan N. Baer⁴, Francesca Barone⁵, Hendrika Bootsma⁶, Simon Bowman⁷, Pilar Brito Zeron⁸, Divi Cornec⁹, Thomas Doerner¹⁰, Salvatore De Vita¹¹, Benjamin Fisher¹², Daniel S. Hammenfors¹³, Malin V. Jonsson¹⁴, Xavier Mariette¹⁵, Vera Milic¹⁶, Hideki Nakamura¹⁷, Wan-Fai Ng¹⁸, Emmanuel Nowak², Manuel Ralos-Casals¹⁹, Astrid Rasmussen²⁰, Raphaèle Seror²¹, Caroline Shiboski²², Takashi Nakamura²³, Arjan Vissink²⁴, Alain Saraux²⁵ and Valérie Devauchelle-Pensec¹, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²INSERM CIC 1412, Brest Medical University Hospital, Brest, France, ³Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ⁶Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ⁸Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Spain, ⁹CHU Brest, Brest, France, ¹⁰Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany, ¹¹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ¹²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ¹³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, Bergen, Norway, ¹⁴Section for Oral and Maxillofacial Radiology, Department of Clinical Dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ¹⁵Université Paris Sud, Paris, France, ¹⁶Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Serbia, ¹⁷Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹⁸Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹⁹Department of Medicine, University of Barcelona, Barcelone, Spain, ²⁰Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²¹Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²²Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, CA, ²³Department of Radiology and Cancer Biology, Nagasaki University School of Dentistry, Nagasaki, Japan, ²⁴Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²⁵Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France
Background/Purpose: The common classification criteria sets of primary Sjogren syndrome, did not considered the ultrasonography (US) of the major salivary glands as a useful item.…
Abstract Number: 878 • 2017 ACR/ARHP Annual Meeting
Diagnosis of Salivary Gland Lymphoma in Sjogren’s Syndrome Utilizing Ultrasound-Guided Core Needle Biopsies
Alan N. Baer¹, Thomas Grader-Beck¹, Brendan Antiochos¹, Julius Birnbaum¹, Qing Kay Li², Deborah Belchis² and Joel Fradin³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Radiology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Ultrasound (US)-guided core needle biopsy (CNB) with or without concomitant fine needle aspiration (FNA) is a standard method for pre-operative evaluation of salivary gland…
Abstract Number: 879 • 2017 ACR/ARHP Annual Meeting
Association of Venous Thromboembolism with Spondyloarthopathies Among Hospitalized Patients – Data from National Inpatient Sample
Dilli Poudel¹, Rashmi Dhital², Raju Khanal², Pragya Shrestha³, Sijan Basnet², Sushil Ghimire² and Paras Karmacharya⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal Medicine, Reading Health System, West Reading, PA, ³Internal medicine, Reading Health System, West Reading, PA, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Venous thromboembolism (VTE) encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE) is the third most common cause of death related to cardiovascular disease…
Abstract Number: 880 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Désirée van der Heijde¹, Dafna D Gladman², Oliver FitzGerald³, Arthur Kavanaugh⁴, Daniela Graham⁵, Cunshan Wang⁵ and Lara Fallon⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴University of California San Diego School of Medicine, La Jolla, San Diego, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients…
Abstract Number: 881 • 2017 ACR/ARHP Annual Meeting
Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study
Elizabeth G. Araujo¹, Matthias Englbrecht², Sabrina Hoepken¹, Stephanie Finzel³, Axel J. Hueber², Juergen Rech⁴ and Georg Schett¹, ¹Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: IL-23 is considered to play an important role in the development of enthesitis. Ustekinumab (UST), a combined inhibitor of IL-12/IL-23 shows efficacy in psoriatic…
Abstract Number: 882 • 2017 ACR/ARHP Annual Meeting
A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients
Keith Colaco^1,2, Dana Jerome³, Jensen Yeung^4,5, Noah Ivers^6,7,8, Carol Kitai⁷, Chandra Farrer³ and Lihi Eder^1,9, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Women's College Hospital, Toronto, ON, Canada, ⁴Dermatology, Women's College Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada, ⁸Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients is high, with delays in diagnosis contributing to poor patient outcomes. We aimed to…
Abstract Number: 883 • 2017 ACR/ARHP Annual Meeting
The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study
Jonathan Chan¹, Anthony So², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE)(pulmonary embolism [PE] and deep vein thrombosis[DVT]) is a potentially life threatening disease. Previous hospital-based studies have shown an increased risk of…
Abstract Number: 884 • 2017 ACR/ARHP Annual Meeting
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Dafna D Gladman¹, Christina Charles-Schoeman², Iain B. McInnes³, Douglas J. Veale⁴, Bruce Thiers⁵, Daniela Graham⁶, Cunshan Wang⁶, Thomas Jones⁷, Robert Wolk⁶ and Ryan DeMasi⁷, ¹Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of California, Los Angeles, Los Angeles, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴St. Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Medical University of South Carolina, Charleston, SC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…
Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting
48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
David Wofsy¹, David A. Isenberg², Frédéric A. Houssiau³, Mary Anne Dooley⁴, Neil Solomons⁵ and Simrat Randhawa⁶, ¹Rheumatology, UCSF, San Francisco, CA, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁴UNC Kidney Centre, Chapel Hill, NC, ⁵Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁶Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
Abstract Number: 886 • 2017 ACR/ARHP Annual Meeting
CC-220 Decreases B-Cell Subsets and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus (SLE) Patients and Is Associated with Skin Improvement: Pharmacodynamic Results from a Phase IIa Proof of Concept Study
Victoria P Werth¹, Richard Furie², Allison Gaudy³, Ying Ye³, Shimon Korish³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²Northwell Health, Great Neck, NY, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a high affinity ligand for cereblon with immunomodulatory properties, currently in development for the treatment of Systemic Lupus Erythematosus as well as…
Abstract Number: 887 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose, Safety, and Pharmacokinetics Study of CC-220 in Subjects with Systemic LUPUS Erythematosus
Richard Furie¹, Victoria P. Werth², Allison Gaudy³, Ying Ye³, Shimon Korish³, Ada Azaryan³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹Northwell Health, Great Neck, NY, ²University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a CUL4CRBN E3 ubiquitin ligase modulator that binds to cereblon and leads to potent and deep reduction of the transcription factors Ikaros(IKZF1)…
Abstract Number: 888 • 2017 ACR/ARHP Annual Meeting
Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus
Joan T. Merrill¹, Renee S. Martin², William Shanahan², Morton Scheinberg³, Kenneth C. Kalunian⁴ and David Wofsy⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Anthera, Hayward, CA, ³Department of Immunology, Center for Clinical Immunology, Sao Paulo SP, Brazil, ⁴Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁵Rheumatology, UCSF, San Francisco, CA
Background/Purpose: The Phase 3 CHABLIS-SC1 trial (NCT01395745) evaluated blisibimod, an inhibitor of B-cell activating factor (BAFF), in SLE. Prior SLE trials suggested that treatments are…
Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)
Eric F Morand¹, Joan T. Merrill², Amy H. Kao³, Cristina Vazquez-Mateo³, Stephen Wax⁴, Peter Chang⁴, Kishore Pudota³ and David A. Isenberg⁵, ¹Monash University, Melbourne, Australia, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment. For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…
Abstract Number: 890 • 2017 ACR/ARHP Annual Meeting
Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE
Tineke Kraaij¹, Sylvia W.A. Kamerling¹, Esther N.M. de Rooij¹, Paul L. van Daele², O.W. Bredewold¹, Jaap A. Bakker³, Ingeborg Bajema⁴, Hans U. Scherer⁵, Rene E.M. Toes⁵, Tom W.J. Huizinga⁵, Ton Rabelink¹, Cees van Kooten¹ and Y.K. Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ³Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, ⁴Pathology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Neutrophil extracellular traps (NETs) are auto-antigenic DNA strands and potentially give rise to SLE-specific autoantibodies that can deposit in glomeruli. It has been shown…
Abstract Number: 891 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan
Yoshikazu Nakaoka¹, Mitsuaki Isobe², Syuji Takei³, Yoshiya Tanaka⁴, Tomonori Ishii⁵, Shumpei Yokota⁶, Akira Nomura⁷, Seitaro Yoshida⁷ and Norihiro Nishimoto⁸, ¹Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ²Sakakibara Heart Institute, Tokyo, Japan, ³Pediatrics of Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁶Laboratory of Pediatric Research, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁸Department of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ), a humanized anti–IL-6 receptor antibody, showed a favorable trend toward relapse suppression in patients (pts) with refractory Takayasu arteritis (TAK) in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].